<DOC>
	<DOCNO>NCT01215942</DOCNO>
	<brief_summary>The primary purpose study help answer LY2127399 safe effective long-term treatment patient Rheumatoid Arthritis . This study comprise 2 period : Period 1 - unblinded treatment 240 week patient enroll Study H9B-MC-BCDO ( BCDO ) ( NCT01202760 ) Study H9B-MC-BCDV ( BCDV ) ( NCT01202773 ) 168 week patient enroll Study H9B-MC-BCDM ( BCDM ) ( NCT01198002 ) . Period 2 - 48 week post treatment follow</brief_summary>
	<brief_title>An Open Label Study Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Completion 24 week participation Study H9BMCBCDO Study H9BMCBCDV , complete 100 week participation Study H9BMCBCDM Woman must pregnant , breastfeeding , become pregnant study Current symptoms serious disorder illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>